KYMR

Kymera Therapeutics, Inc. (KYMR) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics using targeted protein degradation (TPD). The company has no approved products and generates revenue solely through collaboration agreements. As of June 30, 2026, the company had 83,150,618 shares of common stock outstanding.

Key Financial Metrics

Note: All financial figures are in thousands unless otherwise noted. The company reported no debt other than lease liabilities.

Material Changes vs. Prior Period

• Revenue Surge: Collaboration revenue increased significantly to $65.0 million in Q2 2026 from $11.5 million in Q2 2025. This was driven by a $45.0 million option exercise payment from Gilead Sciences (CDK2 program) and a $20.0 million milestone payment from Sanofi (IRAK4 program).
• Expense Growth: Operating expenses rose to $140.6 million in Q2 2026 from $96.0 million in Q2 2025. Research and Development (R&D) expenses increased by $41.1 million, primarily due to a $23.5 million increase in costs for the STAT6 program and higher personnel/overhead costs.
• Liquidity Position: Total cash, cash equivalents, and marketable securities decreased to approximately $1.505 billion as of June 30, 2026, from $1.598 billion at year-end 2025, reflecting operating cash burn and investment activity.
• Net Loss Improvement: Despite higher expenses, the net loss narrowed to $61.2 million in Q2 2026 compared to $76.6 million in Q2 2025, largely due to the spike in collaboration revenue.

Guidance, Outlook, and Risks

• Outlook: Management believes current liquidity ($1.505 billion) is sufficient to fund operations into 2029, covering multiple clinical inflection points. The company expects to continue incurring significant operating losses as it advances clinical trials.
• Pipeline Updates:
  • STAT6 (KT-621): Fast Track Designation received for atopic dermatitis (Dec 2025) and asthma (Apr 2026). Phase 2b trials ongoing.
  • IRAK4 (KT-485): Sanofi dosed the first participant in the Phase 1 trial in June 2026, triggering a $20 million milestone.
  • CDK2 (KT-200): Gilead exercised its option to license the program in April 2026, triggering a $45 million payment.
• Risks:
  • Capital Needs: The company will require substantial additional funding in the future. Failure to raise capital could force delays or discontinuation of programs.
  • Development Uncertainty: As a clinical-stage company, there is no guarantee that product candidates will achieve safety, efficacy, or regulatory approval.
  • Collaboration Dependence: Future revenue is contingent on the success of partners (Sanofi, Gilead) in advancing shared programs.
  • Regulatory & Geopolitical: Risks include FDA delays, potential government shutdowns, and the impact of the BIOSECURE Act on supply chains involving foreign entities.

Investor Verification Checklist

• Cash Runway: Verify the $1.505 billion liquidity figure and the management estimate of funding sufficiency through 2029.
• Revenue Recognition: Confirm the accounting treatment of the $45 million Gilead option exercise and $20 million Sanofi milestone as non-recurring or milestone-based revenue.
• R&D Spend Allocation: Review the specific increase in STAT6 program costs ($23.5 million increase QoQ) to ensure alignment with clinical trial progress.
• Collaboration Terms: Assess the remaining potential milestone payments ($665 million from Gilead; $955 million from Sanofi) and the probability of their achievement.
• Equity Dilution: Monitor the 15.8 million pre-funded warrants outstanding and the potential for future equity raises given the burn rate.